Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qinghai Spring Medicinal Resources Technology Co has a current ratio of 17.66. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
SHSE:600381's Current Ratio is ranked better than 97.1% of 1000
companies
in the Drug Manufacturers industry
Industry Median: 2
vs SHSE:600381: 17.66
Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Qinghai Spring Medicinal Resources Technology Co Current Ratio Related Terms
Qinghai Spring Medicinal Resources Technology Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qinghai Spring Medicinal Resources Technology Co Current Ratio Chart
Qinghai Spring Medicinal Resources Technology Co Annual Data
SHSE:600381 vs ZTS, UTHR: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Qinghai Spring Medicinal Resources Technology Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qinghai Spring Medicinal Resources Technology Co Current Ratio vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) has a Current Ratio of 17.66 as of Mar. 2026. This is 49% below median its historical median of 34.88. Over the past decade, Qinghai Spring Medicinal Resources Technology Co's Current Ratio has ranged from 4.96 to 111.64. According to the industry distribution chart, Qinghai Spring Medicinal Resources Technology Co ranks #29 out of 1000 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Qinghai Spring Medicinal Resources Technology Co's Current Ratio too high?
Qinghai Spring Medicinal Resources Technology Co's current Current Ratio of 17.66 is 49% below median its 10-year median of 34.88. Over the past 10 years, this metric has ranged from a low of 4.96 to a high of 111.64. The Drug Manufacturers industry median Current Ratio is 2.00. Qinghai Spring Medicinal Resources Technology Co's value of 17.66 is 783% above this industry median. Based on the distribution chart, Qinghai Spring Medicinal Resources Technology Co ranks #29 out of 1000 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Qinghai Spring Medicinal Resources Technology Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qinghai Spring Medicinal Resources Technology Co's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Qinghai Spring Medicinal Resources Technology Co ranks #29 out of 1000 companies for Current Ratio. This places Qinghai Spring Medicinal Resources Technology Co in the top 3% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Qinghai Spring Medicinal Resources Technology Co's value of 17.66 is 783% above this benchmark. Historically, Qinghai Spring Medicinal Resources Technology Co's own Current Ratio has ranged from 4.96 to 111.64 over the past decade. While the company's 10-year median is 34.88 vs. the industry median of 2.00, Qinghai Spring Medicinal Resources Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 1,000 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qinghai Spring Medicinal Resources Technology Co's current Current Ratio of 17.66 is 783% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qinghai Spring Medicinal Resources Technology Co's current Current Ratio is 17.66, which is 49% below median its own 10-year median of 34.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qinghai Spring Medicinal Resources Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.85, compared to a current price of ¥4.20 — trading 28.2% below its estimated fair value. The current Current Ratio is 17.66, which is 49% below median its 10-year median of 34.88 and 783% above the Drug Manufacturers industry median of 2.00. Qinghai Spring Medicinal Resources Technology Co's overall GF Score™ is 68/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Qinghai Spring Medicinal Resources Technology Co (SHSE:600381), the current Current Ratio is 17.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) Overvalued in 2026?
Based on GuruFocus' analysis, Qinghai Spring Medicinal Resources Technology Co stock appears to be undervalued.
The current stock price of ¥4.20 is trading 28.2% below its estimated GF Value™ of ¥5.85.
GuruFocus considers Qinghai Spring Medicinal Resources Technology Co to be Modestly Undervalued.
Key valuation signals for SHSE:600381:
Current Ratio: 17.66 (49% below median its 10-year median of 34.88)
GF Value™: ¥5.85 vs. price of ¥4.20 (28.2% below fair value)
Industry Position: 783% above the Drug Manufacturers median (#29 of 1000)
No single metric tells the full story. See the SHSE:600381 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qinghai Spring Medicinal Resources Technology Co Business Description
Qinghai Spring Medicinal Resources Technology Co Ltd is a China-based company that principally engaged in the integrated development, utilization, production, sales, and consulting services of the natural advantageous resources on the Qinghai-Tibet plateau, as well as the development and utilization of other biological resources. The Company's main products are the cordyceps sinensis series products under the Verygrass brand, which includes cordyceps sinensis pure powder tablet, processed cordyceps sinensis, and raw cordyceps sinensis.
68GF Score
Get the complete analysis for SHSE:600381
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600381 has been successfully added to your 
